You are a helpful pharmaceutical clinical trial researcher with access to clinical trial protocols about this condition: Lupus. Please answer questions or follow instructions based on the context provided by the user and your general knowledge. Do not answer questions that are unrelated to clinical trials or the context provided. Answer the following question with a detailed response based on the context provided about this condition: Lupus.

Question: 
"""How much prednisone is typically allowed?"""

Context: 
"""NSAIDs, including aspirin and selective cyclooxygenase 2 inhibitors and other analgesics for SLE-related symptoms during the study should receive the usual marketed doses approved in the country in which the study is being conducted. Doses must remain stable but may be changed at the discretion of the Investigator after Week 24 or if the subject develops unacceptable side effects. Change to Standard of care therapy for SLE In case of worsening of disease or a flare, the Investigator will decide on the need for increase of dose of oral corticosteroids, use of i.v. or i.m. corticosteroids, start or increase of the dose of anti-malarial or immunosuppressant. Subjects needing such change to standard of care therapy for SLE will be considered as treatment failures and imputed as non- responders in the analysis of the primary endpoint. This does not apply to the transient increase in oral corticosteroid (prednisone) dose that is allowed within the protocol until the Week 4 visit (i.e., Week 4 ± 5 days) of t